TURKISH JOURNAL OF ONCOLOGY 2022 , Vol 37 , Num 1
Role of Consolidative Thoracic Radiotherapy for Extensive-stage Small Cell Lung Cancer: Trod Thoracic Oncology Study Group 08-006 Multi-institutional Study
Güler YAVAŞ1,Esra KORKMAZ KIRAKLI2,Meltem DAĞDELEN3,Erkan TOPKAN4,Mert SAYNAK5,Fazilet ÖNER DİNÇBAŞ3,Yurday ÖZDEMİR5,Çağdaş YAVAŞ1,Sümerya Duru BİRGİ6,Serap AKYÜREK6
1Department of Radiation Oncology, Baskent University, Ankara-Turkey
2Department of Radiation Oncology, University of Health Sciences, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir-Turkey
3Department of Radiation Oncology, Istanbul University-Cerrahpaşa, Cerrahpasa Faculty of Medicine, Istanbul-Turkey
4Department of Radiation Oncology, Baskent University, Adana Dr. Turgut Noyan Application and Research Center, Adana-Turkey
5Department of Radiation Oncology, Trakya University, Edirne-Turkey
6Department of Radiation Oncology, Ankara University, Ankara-Turkey
DOI : 10.5505/tjo.2021.3420 OBJECTIVE
We aimed to evaluate the role of consolidative thoracic radiotherapy (TRT) in patients with extensivestage small cell lung cancer (ES-SCLC).

METHODS
The clinical data for 151 patients with the diagnosis of ES-SCLC treated with consolidative TRT from six different hospitals from Turkey analyzed.

RESULTS
The median age of the patients was 61 years (range 36-83 years). The median dose of radiotherapy (RT) was 45 Gy (range: 30-66 Gy) applied in median 25 fractions (range 10-34 fractions). For 151 assessable patients, the median survival time (MST) was 14 months (range: 12.6-15.3). The patients who has complete response and partial response had 16 months, and 14 months of MST. In multivariate analyses prophylactic cranial irradiation (PCI) (p=0.011), female gender (p=0.017), and comorbidity (p=0.006) were found as significant parameters associated with survival. The MSTs were 12 months in patients without comorbidity, and 16 months for the patients with at least one comorbid disease. The patients who received PCI had improved MSTs when compared the ones without PCI (16 months vs. 12 months). There was a trend towards improved overall survival times in patients who received EQD2 ≥47 Gy RT doses (p=0.08).

CONCLUSION
Female gender, use of PCI, and unavailability of comorbid disease were associated with improved survival in ES-SLCL patients. There was a trend towards overall survival times in patients who received ≥47 Gy EQD2 doses; however, we believe that this statistical insignificance was related to our limited patient numbers. Keywords : Consolidative; extensive stage; small-cell lung cancer; survival; thoracic radiotherapy